Evidence map›Paper›PMID 41000090›Full record

ArticleO&G open2025

Financial Toxicity Survey in Patients With Gynecologic Cancer.

Alana Lanser, Indira Pachipala, Rachael Piver, Bunja Rungruang, Sharad Ghamande, Sharad Purohit, Katherine P Richardson, Jessa Suhner, Robert Higgins, Marian Johnson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alana LanserGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Indira PachipalaGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Rachael PiverGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Bunja RungruangGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Sharad GhamandeGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Sharad PurohitGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Katherine P RichardsonGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Jessa SuhnerGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Robert HigginsGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
Marian JohnsonGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.
David P MysonaGeorgia Cancer Center and the Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University, and the Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the sensitivity, specificity, and positive and negative predictive values of the COST (Comprehensive Score for Financial Toxicity) survey for predicting whether patients would report altering spending habits, borrowing money, not filling prescriptions, or experiencing an inability to afford groceries secondary to cancer care costs in a population of patients with gynecologic cancer.

methodsThis was a single-institution, cross-sectional study of patients with gynecologic cancer within 5 years of initial diagnosis or disease recurrence. Patients completed a one-time COST survey and were screened for altering spending habits, borrowing money, not filling prescriptions, or experiencing food insecurity.

resultsA total of 323 patients consented and completed the survey; their mean age was 63 years, and 36.5% self-identified as Black. The mean COST score was 22. The COST score had an area under the curve value of 0.92 for predicting whether a patient would report altering spending habits, borrowing money, not filling prescriptions, or experiencing food insecurity. The cutoff COST score to maximize sensitivity and specificity was 26. At this cutoff, the score was 83.1% sensitive and 88.2% specific and had a positive predictive value of 92.9% and a negative predictive value of 73.7% for identifying those who would screen positive for reporting altering spending habits, borrowing money, delaying buying medications, or experiencing food insecurity.

conclusionOur data indicate that the COST score, a measure of financial toxicity, is associated with social determinants of health in patients with gynecologic cancer. The COST score may help to predict additional needs outside of financial assistance.

Identifiers

PMID41000090
PMCPMC12421981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.